Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘bintrafusp-alfa’

Off the Beaten ASCO21 Track Part 1

There’s always a lot of time and attention focused around phase 3 clinical trial readouts at ASCO, but what about some of the hidden gems where we can learn quite a bit from earlier developments?

This is a two-part series this week where we go off the beaten track on the road less travelled to explore some novel approaches, which may or may not make an impact.

Don’t forget we can often learn as much from negative studies as we do from positive ones because they can teach us what not to do in terms of future design of anti-cancer therapies.

New product development is very much a process of Kaizen, or continuous improvement where we adapt both from what went less well as well as what worked really well.

This year’s ASCO data drop has some important lessons embedded within for those intrigued to dig deeper and pay attention to the finer details…

To learn more about our pre-ASCO meeting analysis to can get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Highlights and lowlights from the ASCO21 data drop

It still feels really weird not to be heading off to Chicago O’Hare in a few weeks

Every year at ASCO we take a quick look at various trials which jump out from the first pass of the data once the abstracts become available then follow up with more in-depth previews later.

There are some winners and losers in this mix, as well as some hidden gems and informative analyses to think about.

So without further ado – what stood out this year for better or worse?

To learn more about our pre ASCO meeting analysis to can get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

ESMO20 Preview 3 Developmental Therapeutics – IO therapies

Remember the good old days at ESMO17 in Madrid? Sadly there’s no face to face networking at this year’s ESMO20 virtual meeting!

In this third ESMO 2020 Preview the focus is on early stage immunotherapies – we’ll cover targeted therapies in a separate review article.

As new regimens evolve involving multiple immune targets, this complexity brings with it a greater need to understand cell-cell interactions – not just immune cell relationships, but also oncogenic, metabolic, and even epigenetic ones. How do they all fit together and what happens when we interfere with those relationships therapeutically?

Often the simple answer is we don’t know until we head into the clinic, I’m afraid.

Beyond the obvious phase 3 IO readouts in the various Presidential symposia and Proffered oral sessions there are quite a few emerging ideas – old ones with a twist as well as entirely new ones – which we can consider and discuss.

Here, we highlight five key IO areas related to cancer immunotherapy and explore the various concepts as preparation for the upcoming meeting…

To learn more from our oncology analysis and get a heads up on insights and commentary pertaining to ESMO 2020, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!